Xinlitai releases Phase I research data on SiRNA therapy for hypertension
On March 31, 2026, Xinli Tai announced that it had recently unveiled the first SAL0132 (GW906) at the 2026 American College of Cardiology Scientific Annual Meeting (ACC.26)! Based on clinical data, SAL0132 (GW906) is an SRNA drug that utilizes GaINAc coupling technology to precisely target hepatic angiotensinogen (AGT). By blocking the RAAS system from the source, SAL0132 (GW906) aims to achieve a long-lasting and stable antihypertensive effect through a long-term mechanism of action, thereby improving patient compliance. In 2025, Xinli Tai obtained exclusive licensing rights for the intellectual property and technical information related to the raw materials and preparations of the AGT SiRNA drug SAL0132 (GW906) under development by Chengdu Guowei in the Chinese market (i.e. mainland China, Taiwan, Hong Kong, and Macao Special Administrative Regions, the same below), including but not limited to product research and development, registration, production, and commercialization. Currently, SAL0132 (GW906) is undergoing phase I clinical trials in patients with primary hypertension.
significance:
Xinlitai releases Phase I research data on siRNA therapy for hypertension
Provide new antihypertensive treatment options: SAL0132 (GW906) is an siRNA drug that uses GalNAc coupling technology to accurately target hepatic angiotensinogen (AGT), achieving blood pressure reduction by blocking the RAAS system from the source. This provides a new treatment mechanism and drug selection for hypertensive patients, especially for those who have poor response or resistance to existing antihypertensive drugs, which may bring new treatment hope.
Pursuing long-lasting and stable blood pressure reduction: This drug aims to achieve long-lasting and stable blood pressure reduction effects through a long-lasting mechanism of action, thereby improving patient compliance. Stable control of blood pressure is crucial for reducing the risk of hypertension complications such as cardiovascular and cerebrovascular diseases, kidney diseases, etc., which can help improve the long-term prognosis and quality of life of patients.
Promoting domestic pharmaceutical research and innovation: Xinlitai has obtained exclusive licensing rights for relevant intellectual property and technical information in the Chinese market, and has conducted clinical trials, which reflects the active participation and progress of domestic pharmaceutical companies in the field of innovative drug research and development, and helps to enhance China's research and development level and international competitiveness in the field of hypertension treatment.
Novo Nordisk Amycritin launches first phase I clinical trial
On March 31, 2026, according to the website of the US Clinical Trial Registry, Novo Nordisk launched the first Sichuan phase clinical trial (AMAZE 12) of Zenagamtide (Amycritin, NNC0487-0111) in overweight populations
Zenagamtide is a single-molecule agonist that acts on glucagon like peptide-1 receptor (GLP-1 R) and amylin receptor (AMYR), and is suitable for subcutaneous injection once a week and oral administration once a day. AMAZE 12 is a global, multicenter clinical trial (n=600) aimed at evaluating the efficacy and safety of Zenagamtide (subcutaneous injection, once a week) compared to placebo. The main endpoint of the study was the change in the variational ratio of body weight among participants between weeks 40-92. Here it is! /In the Chuanqi study (NN9490-7613), obese or overweight subjects who received Zenagamtide treatment for 36 weeks experienced a weight loss of 24.3% compared to only 1.1% in the placebo group. In the Sichuan study, after 36 weeks of Zenagamtide treatment, the highest decrease of HbA1c level in subjects with type 2 diabetes was -1.8%, while that in the placebo group was -0.2%
The highest decrease in weight was 14.5%, while the placebo group showed a decrease of 2.6%.
Benefits:
Novo Nordisk Amycritin launches first phase III clinical trial
It brings new hope for overweight and type 2 diabetes patients: Zenagamtide (Amycretin), as a single molecule agonist, acts on glucagon like peptide-1 receptor (GLP-1R) and amylin receptor (AMYR), showing significant weight loss and improved blood glucose control in previous studies. For overweight people and type 2 diabetes patients, this may be a more effective treatment drug, which helps to reduce weight, improve metabolic indicators, and reduce the risk of related complications.
Promote the development of obesity and diabetes treatment: AMAZE 12, as a global, multi center clinical trial, will further verify the effectiveness and safety of Zenagamtide, and provide scientific basis for the broad application of this drug in the future. If the trial is successful, it will provide new strategies and methods for the treatment of obesity and diabetes, and promote the development and progress of these two fields.
In general, these two news represent the new progress in the field of medical research and development in the treatment of major chronic diseases such as hypertension, obesity and diabetes, which is expected to provide more effective treatment methods for patients and improve their health conditions, and also reflect the continuous efforts and positive results of the global pharmaceutical industry in innovative drug research and development.
